=> d ibib abs hitstr 1-7

ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1297978 CAPLUS

DOCUMENT NUMBER: 150:56371

TITLE: First synthesis of novel spin-labeled derivatives of

camptothecin as potential antineoplastic agents
AUTHOR(S): Liu, Ying-Oian; Tian, Yuan; Yang, Liu; Zhan,

Zong-Cheng

CORPORATE SOURCE: School of Pharmacy, Lanzhou University, Lanzhou,

730000, Peop. Rep. China

SOURCE: European Journal of Medicinal Chemistry (2008),

43(11), 2610-2614

CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Elsevier Masson SAS

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 150:56371

GI

AB In an effort to improve the stability of labile lactone ring and water solubility of camptothecin, five novel spin-labeled camptothecin derivs. were synthesized by a simple modification of the carbodimide method using the combination of scandium triflate (Sc(Off)3) and 4-dimethylaminopyridine (DMAP), and the in vitro pharmacokinetic determination of the lactones of representative compound I showed

that the biol. life span of their lactone forms in human and mouse plasma significantly increased when compared with their mother compound camptothecin. Also, the in vitro cytotoxicity of the compds. against human bladder cancer T-24 showed either similar or better activity than that of the parent drug, camptothecin, and clin. available drug, irinotecan.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:708475 CAPLUS

DOCUMENT NUMBER: 143:326492

TITLE: Radiosynthesis of carbon-11-labeled

camptothecin derivatives as potential positron

emission tomography tracers for imaging of

topoisomerase I in cancers

AUTHOR(S): Gao, Mingzhang; Miller, Kathy D.; Sledge, George W.;

Zheng, Qi-Huang

CORPORATE SOURCE: Department of Radiology, Indiana University School of

Medicine, Indianapolis, IN, 46202, USA

SOURCE: Biogramic & Medicinal Chemistry Letters (2005).

15(17), 3865-3869

CODEN: BMCLE8: ISSN: 0960-894X

PUBLISHER: Elsevier B.V. DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:326492
AB Four carbon-11-labeled camptothecin derivs.,

9-[11C]methoxy-20(S)-camptothecin ([11C]5), 10-[11C]methoxy-20(S)-camptothecin ([11C]7),

9-nitro-10-[11C]methoxy-20(S)-camptothecin ([11C]9), and

9-[([11C]trimethylamino)methyl]-10-hydroxy-20(S)-camptothecin ([11C]11), have been synthesized as potential positron emission tomog, tracers for

imaging of topoisomerase I in cancers.

REFERENCÉ COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:546425 CAPLUS

DOCUMENT NUMBER: 141:106651

TITLE: Preparation of isotope labeled

KIND DATE

camptothecin derivatives

INVENTOR(S): Giribone, Danilo; Forino, Romualdo; Barbugian, Natale;

Fontana, Erminia

PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy

SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

FAIENI NO.					KIND		DAIL		AFFLICATION NO.				DAIL					
WO	0 2004056398				A1		20040708		WO 2003-EP14801					20031219				
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	
		NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ΤJ,	
		TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	zw		
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	
		BY,	KG,	ΚZ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	
		ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	
		TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG
								CA 2003-2509418										
ΑU	2003296720			A1 20040714			AU 2003-296720					20031219						
EP	1578456			A1 20050928			EP 2003-813596											
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE,	SI,	LT,	LV,	FΙ,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK		
BR					A													
	2006510700			T														
MX	2005006746			A		2005	0908		MX 2005-6746				20050620					

APPLICATION NO

DATE

US 2006-540081 A1 20061214 20060719 US 20060281776 EP 2002-80413 A 20021220 W 20031219 PRIORITY APPLN. INFO.: WO 2003-EP14801

OTHER SOURCE(S): CASREACT 141:106651: MARPAT 141:106651

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

The present invention provides isotope labeled camptothecin analogs I [R1 = OH, R'; R2, R3, R4, R5, R6, R7, R8, R9 = 2H, H; X1, X2, X3, X4, X5, X6, X7, X8, X9 = 13C, C; Y = 15N, N; R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20 = 2H, H; X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20 = 13C, C; Y1, Y2 = 15N, N; with the proviso that at least one of C, H or N is an isotope], or their pharmaceutically acceptable salts, including irinotecan and SN-38, a process for their preparation and their use as internal stds. in anal. methods. Thus, labeled SN-38 II was prepared from 4-methoxyaniline via reaction with CD3CH2CN in PhMe, BCl3 in CH2C12 and AlCl3 in ClCH2CH2Cl, followed by O-demethylation with HBr to give 2-H2N-5-HOC6H3COCH2CD3, which underwent cyclocondensation with pyranoindoletrione III in PhMe containing AcOH and catalytic 4-MeC6H4SO3H. In addition, unlabeled SN-38 was acylated with 1-(chlorocarbonyl)-4-{[15N]-piperidin-1-yl}piperidine or

1-(chlorocarbonyl)-4-(decadeuteropiperidin-1-yl)piperidine. REFERENCE COUNT: THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:468534 CAPLUS 125:157685

DOCUMENT NUMBER:

ORIGINAL REFERENCE NO.: 125:29203a,29206a

TITLE: Stabilities of 3H- and 2H-labeled

camptothecins

AUTHOR(S): Hinz, Hellmuth R.; Harris, Nicholas J.; Giovanella,

Beppino C.; Ezell, Edward L.; Liehr, Joachim G. CORPORATE SOURCE: Stehlin Foundation for Cancer Research, St. Joseph

Hospital, Houston, TX, 77003, USA

SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals

(1996), 38(8), 733-742

CODEN: JLCRD4; ISSN: 0362-4803

Wilev

PUBLISHER: DOCUMENT TYPE: Journal

LANGUAGE: English

Com. available [3H]-camptothecin, labeled mainly at the C-5 position, had AB partially lost the tritium label after recovery from the plasma of a patient injected with this drug or after incubation in plasma at 38° for 72 h. Camptothecin dissolved in CH302H/2H2O, incorporated deuterium at the C-5 position with a 50% uptake after one day at pH 11.0 or after 10-11 days at pH 7.4. At pH 2.0, the deuterium uptake was negligible. Camptothecin, dissolved in deuterated sulfuric acid, incorporated 37 or 80% deuterium at C-14 when heated to 65 or 80°, resp. Com. available [3H]-camptothecin, labeled mainly at the C-5 position, is thus not useful for in vivo metabolism or pharmacokinetic studies due to rapid loss of tritium in plasma. In contrast, [3H]-camptothecin prepared as described in this paper for [2H]-camptothecin is expected to be useful.

ACCESSION NUMBER: 1995:658715 CAPLUS 123:74360

DOCUMENT NUMBER: ORIGINAL REFERENCE NO.: 123:12931a,12934a

TITLE: Antitumor activities of a new indolocarbazole

substance, NB-506, and establishment of

NB-506-resistant cell lines, SBC-3/NB AUTHOR(S): Kanzawa, Fumihiko; Nishio, Kazuto; Kubota, Nachiro;

Saijo, Nagahiro

CORPORATE SOURCE: Pharmacology Division, National Cancer Center Res.

Inst., Tokyo, 104, Japan

SOURCE: Cancer Research (1995), 55(13), 2806-13 CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER:

American Association for Cancer Research DOCUMENT TYPE:

Journal LANGUAGE: English

The novel anticancer glucosyl derivative of indolo-carbazole (NB-506), an inhibitor of DNA topoisomerase I, exhibited strong in vitro cytotoxicity against various human cancer cell lines. In order to elucidate its cytotoxic mechanisms, we established nine NB-506-resistant sublines. Among them, SBC-3/NB#9 was 454 time more resistant to NB-506 than the parent cell line. The SBC-3/NB#9 cells showed cross-resistance only to

topoisomerase I inhibitors, such as

11.7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin and 7-ethyl-10-hydroxy-camptothecin, and not to other anticancer drugs, such as vincristine, vincristine, vinblastine, Adriamycin, etoposide, and teniposide. These results indicate that the difference on the effect of topoisomerase I was considered ot be related to a resistance mechanism. The topoisomerase I activities of nuclear exts. eluted from SBC-3/NB9 cells was only one-tenth of the parent cell activity. A Western blotting study indicated that this lower activity was due to a lower amount of DNA topoisomerase I. Furthermore, we found correlations between topoisomerase I activity and sensitivity to NB-506 in sublines with different degrees of resistance. Accumulation of 3H-labeled NB-506 by SB-3/NB#9 cells was only one-fifth of that by the parent cells, whereas intracellular accumulation of 3H-labeled camptothecin by both cell lines did not

differ. The reduction of accumulation was specific to Nb-506, and this result may explain why the resistance ratio for N-506 was higher than those for 11.7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptotpecin

ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

and 7 ethvl-10-hvdroxv-camptothecin. ACCESSION NUMBER: 1984:530954 CAPLUS DOCUMENT NUMBER: 101:130954 ORIGINAL REFERENCE NO.: 101:19931a,19934a

TITLE: Preparation of tritium-labeled

camptothecin, 10-hydroxycamptothecin and

nevadensin

Zhang, Xin; Ding, Ruigin AUTHOR(S):

Shanghai Inst. Mater. Med., Acad. Sin., Shanghai, CORPORATE SOURCE:

Peop. Rep. China SOURCE:

Hejishu (1984), (2), 47-8 CODEN: NUTEDL; ISSN: 0253-3219

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

Title compds. were prepared by treating camptothecin, 10-hydroxycamptothecin, and nevadensin with CF3CO2H/T2O, Me2SO/T2, and CH3CO2H/T2O, resp.

L1 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1981:498106 CAPLUS

## 10/540.081

DOCUMENT NUMBER: 95:98106

ORIGINAL REFERENCE NO.: 95:16499a,16502a

TITLE: The preparation of tritium- and deuterium-

labeled camptothecin

AUTHOR(S): Ronman, Peter E.; Wani, Mansukh C.; Wall, Monroe E. CORPORATE SOURCE: Research Triangle Inst., Research Triangle Park, NC,

27709, USA

SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals

(1981), 18(3), 319-29

CODEN: JLCRD4; ISSN: 0362-4803

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 95:98106

GI

R Et OH

R1 O I

AB The labeled camptothecins I (R = T, Rl = H; R = H, Rl = D) were prepared from I (R = Rl = H) (II). Thus, II was nitrated, hydrogenated, and brominated to give I (R = Br, Rl = H) which was reduced by T2(g) in the presence of Pd/C to give I (R = T, Rl = H) with a sp. activity of 29 Ci/mol and a radiochem. purity of 595%. Reduction of d-II with D2(g) in the presence of Pd/C for 24 h gave optically active I (R = H, Rl = D).

=> d his

p1

(FILE 'HOME' ENTERED AT 10:17:09 ON 30 APR 2009)

FILE 'CAPLUS' ENTERED AT 10:17:23 ON 30 APR 2009

L1 7 S LABELLED CAMPTOTHECIN OR LABELED CAMPTOTHECIN?

=>